1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Disease Exacerbation

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Disease Exacerbation in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berntzen, DT; Løitegård, T; Thiis-Evensen, E	1

Other Studies

1 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Disease Exacerbation

Article	Year
The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. Annals of nuclear medicine, 2019, Volume: 33, Issue:3 Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden	2019

Article

Year

The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.

Annals of nuclear medicine, 2019, Volume: 33, Issue:3

Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden

2019